References
- Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589
- Grever M R, Lucas D M, Dewald G W, Neuberg D S, Reed J C, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799–804
- Zenz T, Dohner H, Stilgenbauer S. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 439–453
- Austen B, Skowronska A, Baker C, Powell J E, Gardiner A, Oscier D, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007; 25: 5448–5457
- Pettitt A R, Sherrington P D, Stewart G, Cawley J C, Taylor A M, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814–822
- Hillmen P, Skotnicki A B, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616–5623
- Zenz T, Krober A, Scherer K, Häbe S, Bühler A, Benner, et al. Mono-allelic TP53 inactivation is associated with poor prognosis in CLL: results from a detailed genetic characterization with long term follow-up. Blood 2008; 112: 3322–3329
- Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009; 23: 117–124
- Rossi D, Cerri M, Dcambrogi C, Sozzi E, Cresta S, Rasi S, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Ciin Cancer Res 2009; 15: 995–1004
- Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M, et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 2008; 112: 1993–2003
- Zenz T, Häbe S, Dcnzel T, Winkler D, Hallek M, Hensel M, et al. The activity of alemtuzumab is independent of p53 mutational status in fludarabine refractory CLL: final analysis from the CLL2H stxdy of the GCLLSG. Am Oncol 2008; 19: v193
- Zenz T, Mohr J, Eldering E, Kater A P, Bühler A, Kienle D, et al. MiR-34a as part of the chemotherapy resistance network in chronic lymphocytic leukemia. Blood 2008, [Epub ahead of print]